phosphorus-radioisotopes and Prostatic-Neoplasms
phosphorus-radioisotopes has been researched along with Prostatic-Neoplasms* in 45 studies
Reviews
1 review(s) available for phosphorus-radioisotopes and Prostatic-Neoplasms
Article | Year |
---|---|
[Metabolic radiotherapy: what role will it have in 2001?].
Metabolic radiotherapy is a new therapy for management of bone pain in patients with bone metastatic prostate carcinoma. Strontium-89 and Samarium-153 concentrate in bone metastases and radiate them. A pain decrease is obtained in 60-70% of cases. Side effects are a significant hematological depression without great clinical consequences if good therapeutic indications are respected. Our multidisciplinary experience of these radionuclides in 54 performed treatments shows a rate of good responders of 66% with a rate of excellent results (total decrease of pain) in 47%. The therapeutic effectiveness is correlated with pain intensity measured by Visual Analogic Scale (VAS) and equivalent dose of morphine. Radionuclide therapy should be applied to patients as early as possible after establishment of bone metastases. Topics: Adenocarcinoma; Aged; Aged, 80 and over; Analgesics, Opioid; Bone Neoplasms; Clinical Trials as Topic; Double-Blind Method; Forecasting; France; Hematologic Diseases; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Phosphorus Radioisotopes; Prospective Studies; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium; Samarium; Strontium; Strontium Radioisotopes; Treatment Outcome | 2002 |
Trials
1 trial(s) available for phosphorus-radioisotopes and Prostatic-Neoplasms
Article | Year |
---|---|
Irradiation in relapsing carcinoma of the prostate.
Radiation therapy plays a major role in the management of patients with either locally recurrent or metastatic carcinoma of the prostate.. In 23 patients with isolated postprostatectomy local recurrences treated with doses of 60-65 Gy, 17 (74%) had tumor control, and 45% survived relapse-free for 5 years after treatment of the recurrence. Pelvic irradiation has been used to treat patients with elevated prostate-specific antigen (PSA) levels after radical prostatectomy. This was tried, and 17 of 24 patients (70%) showed a significant decrease in PSA levels after irradiation, in five without subsequent elevation. Two of the seven patients with elevated PSA levels later had distant metastases. Local irradiation has been reported to yield excellent relief of symptoms in 100% of patients with hematuria, 80% with urinary outflow obstruction, and 50-70% with ureteral obstruction or pelvic pain secondary to locally advanced prostatic carcinoma. Reirradiation, particularly with brachytherapy (in preliminary studies combined with hyperthermia) has been used in the management of postirradiation prostatic recurrences with satisfactory tumor regression in approximately 75% of patients. The Radiation Therapy Oncology Group (RTOG) reported on the palliative effects of external irradiation on patients with bony metastasis. Approximately 54% of such patients had complete relief, and 29% had partial relief of bone pain. However, the retreatment rate of the bony metastasis was lower in the patients receiving higher doses. In a RTOG protocol in which all patients received local irradiation for osseous metastases, 77 were randomized to receive elective hemibody irradiation and 69, local treatment only. The frequency of additional treatment at 1 year was lower in the hemibody irradiation group (54% versus 78%). Occasionally, brain, mediastinal, or liver metastasis can be treated with irradiation. Radioactive phosphorus-32 or strontium-89 has been administered for disseminated bony metastasis with improvement of bone pain in approximately 70-80% of treated patients.. The role of irradiation in the treatment of spinal cord compression is discussed. Significant improvement of neurologic function has been reported in 36-60% of the patients, depending on severity of deficit and promptness in instituting emergency treatment. Topics: Bone Neoplasms; Brachytherapy; Brain Neoplasms; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Phosphorus Radioisotopes; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Rhenium; Spinal Cord Compression; Strontium Radioisotopes | 1993 |
Other Studies
43 other study(ies) available for phosphorus-radioisotopes and Prostatic-Neoplasms
Article | Year |
---|---|
(31) P MR spectroscopic imaging combined with (1) H MR spectroscopic imaging in the human prostate using a double tuned endorectal coil at 7T.
Improved diagnostic sensitivity could be obtained in cancer detection and staging when individual compounds of the choline pool can be detected. Therefore, a novel coil design is proposed, providing the ability to acquire both (1) H and (31) P magnetic resonance spectroscopic imaging (MRSI) in patients with prostate cancer.. A two-element (1) H/(31) P endorectal coil was designed by adjusting a commercially available 3T endorectal coil. The two-element coil setup was interfaced as a transceiver to a whole body 7T MR scanner. Simulations and phantom measurements were performed to compare the efficiency of the coil. (1) H MRSI and (31) P MRSI were acquired in vivo in prostate cancer patients.. The efficiency of the (1) H/(31) P coil is comparable to the dual channel (1) H coil previously published. Individually distinguishable phospholipid metabolites in the in vivo (31) P spectra were: phosphoethanolamine, phosphocholine, phosphate, glycerophosphoethanolamine, glycerophosphocholine, phosphocreatine, and adenosine triposphate. (1) H MRSI was performed within the same scan session, visualizing choline, polyamines, creatine, and citrate.. (1) H MRSI and (31) P MRSI can be acquired in the human prostate at 7T within the same scan session using an endorectal coil matched and tuned for (1) H (quadrature) and (31) P (linear) without the need of cable traps and with negligible efficiency losses in the (1) H and (31) P channel. Topics: Aged; Biomarkers, Tumor; Equipment Design; Equipment Failure Analysis; Female; Humans; Magnetic Resonance Imaging; Magnetics; Male; Middle Aged; Phosphorus Radioisotopes; Prostatic Neoplasms; Proton Magnetic Resonance Spectroscopy; Radiopharmaceuticals; Rectum; Reproducibility of Results; Sensitivity and Specificity; Transducers | 2014 |
³²P-chromic phosphate-Poly(L-Lactide) seeds of sustained release and their brachytherapy for prostate cancer with lymphatic metastasis.
This study aims to develop a new agent, the ³²P-chromic phosphate-poly(l-lactide) (³²P-CP-PLLA) seed and to explore its anticancer effect against prostate cancer (Pca) with local lymphatic metastasis in nude mice. ³²P-CP-PLLA seeds of sustained release and nude mouse models of Pca with lymphatic metastasis were prepared. After 4 weeks, the tumor nude mouse models were randomly assigned into five groups. ³²P-CP-PLLA seeds (3.7, 7.4, 14.8, and 0 MBq) and ³²P-CP (14.8 MBq) were implanted in the tumor tissues of the nude mouse models. The following were discussed in this study: (1) the distributions of ³²P-CP-PLLA, (2) the pathological and morphological changes in the tumor and regional lymph nodes, and (3) the changes in white blood cell (WBC) and platelet counts in peripheral blood for toxic reactions. The homemade ³²P-CP-PLLA seed was a regular green cylinder, with an even distribution of mass and radioactivity. After implantation, single-photon emission computed tomograph (SPECT) showed that ³²P was mainly gathered in the tumor and regional lymph nodes. Morphological examinations revealed that necrosis and hemorrhage were around the tumor and focal lymph nodes. The tumor inhibition rates of the five groups were 70.16% ± 5.48%, 80.18% ± 5.84%, 84.97% ± 4.79%, (-), and 78.81% ± 3.13%, respectively. These values were all positive when compared with the control group. As a new homemade agent of pure β-ray, local implantation of the agent increased the focal retention of radioactivity at the target. Moreover, effective half-life showed an obvious damage to the tumor and metastatic foci of Pca. Topics: Animals; Brachytherapy; Cell Line, Tumor; Chromium Compounds; Humans; Lactic Acid; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Phosphates; Phosphorus Radioisotopes; Polyesters; Polymers; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2012 |
[Implantation brachytherapy with 32P-chromic phosphate-poly (L-lactide) delayed-release particles for prostate cancer in nude mice].
To study the effects of implantation brachytherapy with delayed-release particles of 32P-chromic phosphate-poly (L-lactide) (32P-CP-PLLA) on prostate cancer (PCa) in nude mice.. We established a subcutaneous transplantable PCa model in nude mice, and randomly divided them into six groups, Groups A, B and C implanted intratumorally with 32P-CP-PLLA delayed-release particles at 3.7, 7.4 and 14.8 MBq, Groups D, E and F with 125I particles at the same doses as the former three, and another six nude mice were included in Group G as the blank control. Then we killed the mice at 21 days after the treatment, observed the effects of the particles on the morphology of the tumor and their inhibition of tumor growth, counted WBCs and platelets (PLTs) in the peripheral blood, and detected the toxic reaction of the blood.. At 21 days after the treatment, the solid tumor tissues exhibited bleeding and necrotic changes, and the rates of tumor inhibition were positively correlated with the doses of administration. Groups A, B and C showed statistically significant differences from Groups D, E, F and G in the rate of tumor inhibition ([ 65.72 +/- 6.95]%, [77.58 +/- 4.32]% and [82.64 +/- 4.03]% versus [35.61 +/- 5.61]%, [43.30 +/- 6.94]% and [69.01 +/- 4.98]%), WBC count ([1.72 +/- 0.37] x 10(9)/L, [1.23 +/- 0.27] x 10(9)/L and [0.86 +/- 0.25] x 10(9)/L versus [1.45 +/- 0.40] x 10(9)/L, [0.51 +/- 0.24] x 10(9)/L, [0.37 +/- 0.26] x 10(9)/L and [3.96 +/- 0.26] x 10(9)/L), PLT count ([1.18 +/- 0.11] x 10(11)/L, [0.97 +/- 0.10] x 10(11)/L and [0.72 +/- 0.11] x 10(11)/L versus [0.97 +/- 0.15] x 10(11)/L, [0.76 +/- 0.16] x 10(11)/L, [0.64 +/- 0.12] x 10(11)/L and [2.89 +/- 0.21] x 10(11)/L) and body weight ([18.60 +/- 0.66] g, [17.60 +/- 0.39] g and [16.90 +/- 0.68] g versus [17.86 +/- 0.60] g, [15.56 +/- 0.39] g, [14.61 +/- 0.65] g and [19.95 +/- 0.73] g) (P < 0.01).. Intratumoral implantation of 32P-CP-PL-LA is a safe, simple and effective radionuclide interventional therapy for prostate cancer. Topics: Animals; Brachytherapy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorus Radioisotopes; Prostatic Neoplasms | 2010 |
Radionuclide therapy of cancer patients with bone metastases.
We report our experience in the use of radionuclides in the treatment of bone metastases in patients with various primary cancers: breast cancer, prostate cancer, lung cancer, etc.. Eighty-seven patients (53 women, 34 men) with bone metastases were treated for pain relief with either 32-P (71 patients) or 89-Sr (16 patients). Fifty-three of the patients had breast cancer, 27--rostate cancer, 6--lung cancer and 1--kidney cancer. The patients were examined for side effects when 32-P was administered perorally and 89-Sr injected intravenously. We also studied the changes in the levels of hemoglobin, white blood cells (WBCs) count and platelets count.. We found a significant decrease in the WBC and platelet count in the patients treated with 32-P (U = 2.20, P < 0.05 and U = 4.57, P < 0.001) one month after the therapy. These parameters showed no significant decrease in the group treated with 89-Sr. The pain, which was the rationale to use the radioactive isotopes, was relieved and the patients restored their previous mobility.. The fact that 32-P alleviated the grave symptom of pain at the relatively weak radiation dose used (2 mCi) is a strong indication that this radiopharmaceutical can be used successfully for such a purpose, although some authors argue against its use in view of the myelosuppresion it causes. This myelosuppression, however, is mild and transient even without treatment and patients could benefit from this adjuvant treatment to manage the pain syndrome. 89-Sr administered intravenously in a dose of 4mCi also relieves pain efficiently but its use is limited by the cost of the quantity needed for 1 patient and for a single dose. The National Health Insurance Fund currently reimburses for a very limited quantity of this substance which makes the cost of the procedure 15 times as expensive as that using radioactive phosphorus.. Using the radiopharmaceuticals 32-P and 89-Sr provides an additional, easy and efficacious means for palliation of cancer patients with bone metastases, especially those who are refractory to percutaneous irradiation. Topics: Bone Neoplasms; Breast Neoplasms; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Pain; Pain Measurement; Phosphorus Radioisotopes; Platelet Count; Prostatic Neoplasms; Strontium Radioisotopes; Treatment Outcome | 2005 |
Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited.
The role of phosphorus-32 (32P) was evaluated in patients experiencing pain due to skeletal metastases from prostate cancer and refractory to other modes of treatment. Twenty patients received 185 MBq (5 mCi)32P intravenously; 12 patients received a single dose each, five patients were injected twice and three patients three times at 3-month intervals. A blood count and clinical assessment for bone pain, tender sites, mobility and analgesic intake were performed before and 4, 8 and 12 weeks after the administration of 32P. A bone scan was performed before and 12 weeks after therapy. The results showed a significant decrease in pain at 4 weeks and a palliative response persisted for up to 12 weeks. Analgesic medication intake decreased significantly (F = 13.2213, P < 0.0001) and mobility improved after therapy. Quantitative analysis of the bone scans showed a statistically significant reduction in osteoblastic activity in metastatic lesions after therapy (t = -3.80, P < 0.001). Transient myelosuppression after 4 weeks, which was statistically significant for WBC and platelet counts only (F = 3.0226, P = 0.0358; F = 6.2514, P = 0.0009 respectively), returned within normal limits by 8 weeks. We conclude that 32P is an effective and safe therapy for pain palliation. Topics: Aged; Bone Marrow; Bone Neoplasms; Humans; Male; Middle Aged; Pain; Palliative Care; Phosphorus Radioisotopes; Prostatic Neoplasms; Safety | 1999 |
Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone.
Treatment with estradiol-17 beta and testosterone induces epithelial dysplasia and, subsequently, adenocarcinoma in the dorsolateral prostate of NBL rats. The purpose of this study was to determine whether this carcinogenic effect is mediated by genotoxicity. Analogous to adducts produced by estrogens in the male hamster kidney, a target of estrogen carcinogenicity, induction of DNA adducts detectable by 32P-postlabeling was investigated in the prostate target tissue. NBL rats were treated with separate Silastic tubing implants containing testosterone and estradiol-17 beta. Control animals received empty implants. Animals were killed at 8, 16 and 24 weeks after initiation of treatment, and accessory sex glands were sampled for adduct analysis. DNA of the dorsolateral and ventral prostate and the coagulating gland (= anterior prostate) was isolated and analyzed by nuclease P1-enhancement of the 32P-post-labeling assay. DNA adducts were quantitated by Cerenkov counting. An adduct occurred selectively in DNA of the dorsolateral prostate of rats treated with estradiol plus testosterone for 16 or 24 weeks with relative adduct level values of approximately 10 x 10(9), but not in DNA of the ventral or anterior prostate. The adduct was not present in DNA of prostate tissue of rats treated for 8 weeks or in DNA of control tissues. This adduct was unique with respect to chromatographic location and has not been observed before in any tissue of control or hormone-treated animals. Neither the structure of the treatment-induced adduct nor the mechanism of its formation is known. However, the selective occurrence of this adduct in the tissue of origin of the carcinomas and its appearance coinciding with putative preneoplastic lesions and preceding carcinoma development suggests a causal relation between adduct formation and prostate cancer development in testosterone plus estradiol-17 beta-treated rats. Topics: Adenocarcinoma; Animals; Autoradiography; Cricetinae; DNA; DNA Adducts; Estradiol; Male; Phosphorus Radioisotopes; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Testosterone | 1995 |
DNA adducts in target and nontarget tissues of 3,2'-dimethyl-4-aminobiphenyl in rats.
3,2'-Dimethyl-4-aminobiphenyl (DMAB) is a potent carcinogenic aromatic amine which demonstrates multiorgan tropism in rats. Using polyclonal antibodies against DMAB-DNA adducts, an immunohistochemical procedure as well as an ELISA were applied to investigate the relationship between DMAB-DNA adduct formation and tumorigenicity. Dose-related nuclear staining was observed 24 hr after application of the carcinogen but specificity in terms of sites of tumor development was lacking. No observable decrease in staining intensity was evident in most organs by 168 hr after administration of DMAB. Specific DNA lesions which could be responsible for carcinogenesis were not detected by the 32P-postlabeling method. The tumorigenic response of the ventral prostate in five strains of rats was roughly paralleled by DMAB-DNA adduct levels generated in the tissue. Strong enhancement of bladder tumor development by combined administration of the antioxidants, butylated hydroxyanisole, or butylated hydroxytoluene, with DMAB, was well correlated with an increase in DNA adducts. Our findings so far suggest that DNA adduct formation itself does not determine the carcinogenic organotropism of DMAB. Other factors (including cell proliferation and promotion by exogenous agents) may play important additional roles. For individual target organs or tissues, however, there seems to be a correlation between adduct levels and carcinogenic potential. Topics: Aminobiphenyl Compounds; Animals; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Carcinogens; DNA Adducts; Immunochemistry; Male; Phosphorus Radioisotopes; Prostatic Neoplasms; Rats; Rats, Inbred F344; Species Specificity; Testosterone | 1994 |
Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report.
We assessed the ability of 31phosphorus (31P) transrectal magnetic resonance spectroscopy to characterize normal human prostates as well as prostates with benign and malignant neoplasms. With a transrectal probe that we devised for surface coil spectroscopy we studied 15 individuals with normal (5), benign hyperplastic (4) and malignant (6) prostates. Digital rectal examination, transrectal ultrasonography and magnetic resonance imaging were used to aid in accurate positioning of the transrectal probe against the region of interest within the prostate. The major findings of the in vivo studies were that normal prostates had phosphocreatine-to-adenosine triphosphate (ATP) ratios of 1.2 +/- 0.2, phosphomonoester-to-beta-ATP ratios of 1.1 +/- 0.1 and phosphomonoester-to-phosphocreatine ratios of 0.9 +/- 0.1. Malignant prostates had phosphocreatine-to-beta-ATP ratios that were lower (0.7 +/- 0.1) than those of normal prostates (p less than 0.02) or prostates with benign hyperplasia (1.1 +/- 0.2, p less than 0.01). Malignant prostates had phosphomonoester-to-beta-ATP ratios (1.8 +/- 0.2) that were higher than that of normal prostates (p less than 0.02). Using the phosphomonoester-to-phosphocreatine ratio, it was possible to differentiate metabolically malignant (2.7 +/- 0.3) from normal prostates (p less than 0.001), with no overlap of individual ratios. The mean phosphomonoester-to-phosphocreatine ratio (1.5 +/- 0.5) of prostates with benign hyperplasia was midway between the normal and malignant ratios, and there was overlap between individual phosphomonoester-to-phosphocreatine ratios of benign prostatic hyperplasia glands with that of normal and malignant glands. To verify the in vivo results, we performed high resolution magnetic resonance spectroscopy on perchloric acid extracts of benign prostatic hyperplasia tissue obtained at operation and on a human prostatic cancer cell line DU145. The extract results confirmed the differences in metabolite ratios observed in vivo. We conclude that transrectal 31P magnetic resonance spectroscopy can characterize metabolic differences between the normal and malignant prostate. Topics: Adult; Aged; Evaluation Studies as Topic; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Staging; Phosphorus Radioisotopes; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Rectum; Ultrasonography | 1991 |
Phosphorus-32 for intractable bony pain from carcinoma of the prostate.
Although multiple bony metastases from carcinoma of the prostate are common, widespread pain is a much less frequent complication but one which nevertheless presents considerable difficulties in management. Pain may be severe requiring large doses of narcotic analgesics and may render the patient virtually immobile. A total of 53 treatments with radioactive phosphorus-32 were assessed in 46 patients; in addition, five patients died before response was assessable. A worthwhile response in terms of pain reduction and improved mobility was obtained in 87%. Response was subdivided into good and moderate, with response rates of 53% and 34% respectively. The mean age of patients at treatment was 64.6 years, the median 65 years, and 30% of treated patients were 60 years or under. Median survival in the good, moderate and no response groups was 8, 6.5 and 4.5 months respectively. These differences in survival are not statistically significant. Five-year survival was 4.3%. The treatment is not intended to improve survival but with 87% of patients achieving pain relief, 32P should be considered for the treatment of severe bony pain when other options are limited by the widespread nature of the disease. Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Injections, Intravenous; Male; Middle Aged; Pain; Pain Management; Palliative Care; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1990 |
Androgen receptor heterogeneity and phosphorylation in human LNCaP cells.
Androgen receptor heterogeneity and phosphorylation were studied in the human LNCaP cell line. Fluorography after photoaffinity labeling as well as immunoblotting with a specific polyclonal antibody revealed that the human androgen receptor migrated as a closely spaced 110 kD doublet on SDS-polyacrylamide gels. A time-dependent change in the ratio between the two isoforms was not observed after R1881 treatment of intact cells. In nuclear extracts of LNCaP cells that were incubated with [32P]orthophosphate in the presence of 10 nM R1881, a 110 kD phosphorylated protein was demonstrated after immunopurification using a monoclonal antibody against the human androgen receptor. Only a very small amount of this phosphoprotein was detected in the nuclear fraction from cells not treated with R1881. These results indicate that the human androgen receptor in LNCaP cells can be phosphorylated. Topics: Autoradiography; Blotting, Western; Cell Line; Cell Nucleus; Humans; Lymphoma; Male; Molecular Weight; Phosphates; Phosphorus Radioisotopes; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Tumor Cells, Cultured | 1990 |
[Palliative radiophosphorus therapy for analgesia in bone metastases].
Topics: Bone Neoplasms; Humans; Male; Palliative Care; Phosphorus Radioisotopes; Prostatic Neoplasms | 1988 |
Comparison of 32P therapy and sequential hemibody irradiation (HBI) for bony metastases as methods of whole body irradiation.
We report a retrospective study of 15 patients with prostate carcinoma and diffuse bone metastases treated with sodium 32P for palliation of pain at Downstate Medical Center and Kings County Hospital from 1973 to 1978. The response rates, duration of response, and toxicities are compared with those of other series of patients treated with 32P and with sequential hemibody irradiation. The response rates and duration of response are similar with both modalities ranging from 58 to 95% with a duration of 3.3 to 6 months with 32P and from 75 to 86% with a median duration of 5.5 months with hemibody irradiation. There are significant differences in the patterns of response and in the toxicities of the two treatment methods. Both methods cause significant bone marrow depression. Acute radiation syndrome, radiation pneumonitis, and alopecia are seen with sequential hemibody irradiation and not with 32P, but their incidence can be reduced by careful treatment planning. Hemibody irradiation can provide pain relief within 24 to 48 h, while 32P may produce an initial exacerbation of pain. Lower hemibody irradiation alone is less toxic than either upper hemibody irradiation or 32P treatment. Topics: Bone Neoplasms; Humans; Male; Pain; Palliative Care; Phosphorus Radioisotopes; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Whole-Body Irradiation | 1986 |
[Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
In the urological department of the Wilhelminenspital altogether 22 patients with incurable bone pains in metastasizing carcinoma were treated with radioisotopes between 1976 and 1980. 32P and 89Sr were used in a dosage of 3 times 3 mCi and once 1 mCi. A reaction to the therapy could be proved in 46%, in 23% the success could be estimated as very good. Clinic and therapy were discussed with the help of own cases and literature. Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Neoplasm Staging; Palliative Care; Phosphorus Radioisotopes; Prostatic Neoplasms; Strontium Radioisotopes | 1981 |
Carcinoma of the prostate: the treatment of bone metastases by radiophosphorus.
Osseous deposits secondary to advanced carcinoma of the prostate are a common feature of the disease. These deposits are most often seen in the lumbar spine and pelvis and cause severe and intractable pain, often requiring large quantities of strong analgesia for alleviation of pain. Relief of pain can be achieved by external irradiation of these deposits, but this relief may not be permanent and the disease may be so widespread that it is impracticable to treat all the deposits by irradiation. Deposits from carcinoma of the prostrate are usually multiple and all may cause pain at the same time. A method of delivering the radiation to all the deposits at the same time has been sought. Previous studies have shown that radioactive phosphorus (P32) can be used to obtain this localisation of radioactivity at sites of osseous activity. In this study 24 patients with bone metastases from carcinoma of the prostate were treated with radiophosphorus and methyl testosterone, or radiophosphorus with parathormone and calcium. An overall response rate of 58% shows this to be an effective palliative treatment. The results suggest there is a greater response when P32 is used in conjunction with parathormone and calcium, than with methyl testosterone. Topics: Bone Neoplasms; Calcium; Humans; Male; Methyltestosterone; Phosphorus Radioisotopes; Prostatic Neoplasms | 1981 |
Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate.
Radioactive phosphorus effected substantial palliation of intractable bone pain in 17 of 33 (51.5%) women with metastatic carcinoma of the breast and in 14 of 15 (93.3%) men with metastatic carcinoma of the prostate. No significant difference in the overall response rate was found between androgen and parathormone priming prior to radiophosphorus therapy. The degree of response was not dependent on total dose of 32P within the range of 9--18 mCi (333--666 MBq). Myelosuppression was a transient complication in 9 of 33 patients with metastatic breast carcinoma and in 7 of 15 patients with metastatic prostate carcinoma. Symptomatic hypercalcemia was an infrequent complication of radiophosphorus therapy irrespective of the priming regimen. Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluoxymesterone; Humans; Male; Middle Aged; Palliative Care; Parathyroid Hormone; Phosphorus Radioisotopes; Prostatic Neoplasms | 1980 |
32P-sodium phosphate treatment of metastatic malignant disease.
Thirty-four patients with cancer of the breast and 12 with cancer of the prostate were treated with testosterone and 32P-sodium phosphate for relief of pain from bony metastases. Thirty were treated with chemotherapy as well, and 34 were treated with external radiation to single ports for localized pain. Of the 46 patients treated, good results were achieved in 34, fair results in six, and no improvement in six. Subsequent marrow depression necessitated transfusion in 10 patients; no other side effect was observed. Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphorus Radioisotopes; Prostatic Neoplasms | 1979 |
32P-sodium phosphate treatment of metastatic malignant disease.
Thirty-four patients with cancer of the breast and 12 with cancer of the prostate were treated with testosterone and 32P-sodium phosphate for relief of pain from bony metastases. Thirty received chemotherapy as well, and 34 received external radiation to single ports for localized pain. Of the 46 patients, 34 had good results, 6 fair, and 6 were failures. Ten patients needed transfusion for marrow depression; no other side effect was observed. Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Management; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1979 |
[Pain relief of osseous metastases by testosterone potentiated radiophosphorus therapy (author's transl)].
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Neoplasm Metastasis; Pain, Intractable; Palliative Care; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1978 |
[32P] diphosphonate dose determination in patients with bone metastases from prostatic carcinoma.
In an initial safety study, phosphorus-32 (as diphosphonate) was administered intravenously to five patients with painful bone metastases from prostatic carcinoma; two patients received 9 mCi and three were given 3 mCi. Hematological, biochemical, ECG, x-ray, bone-scan data, and clinical observation, were followed for 2 mo. At both dose levels, bone-marrow depression was noted. One of the patients, who received 9 mCi, had only a slight dip in the levels of circulating white blood cells and platelets. The other 9-mCi patient was the only one with discrete metastases by bone scan; he had bone-marrow depression, from which he recovered, and was the only one of the five who had relief of bone pain. Topics: Adenocarcinoma; Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphorus Radioisotopes; Prostatic Neoplasms; Radiotherapy Dosage | 1978 |
Phosphorus-32 for intractable pain in carcinoma of prostate. Analysis of androgen priming, parathormone rebound, and combination therapy.
Thirty-three patients with intractable pain caused by diffuse osteoblastic metastases from carcinoma of the prostate were treated with phosphorus-32 (32P) therapy either androgen priming, parathormone rebound, or a combination of both priming methods. Significant response to pain was achieved in 12 of 19 patients receiving testosterone-potentiated therapy, 0 of 5 patients treated with parathormone alone, and 6 of 9 patients receiving a combination of both priming modalities. It is concluded that androgen priming alone is the simplest and most effective method to be used when 32P therapy is being considered for palliative control of pain in patients with carcinoma of prostate. Topics: Aged; Bone Neoplasms; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain, Intractable; Palliative Care; Parathyroid Hormone; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1977 |
Improvement of findings on bone image in prostatic cancer following testosterone potentiated 32P therapy.
Topics: Aged; Bone Neoplasms; Humans; Male; Neoplasm Metastasis; Pain, Intractable; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1976 |
[Radiation therapy of cancer of the prostate gland].
Topics: Cobalt Radioisotopes; Gold Radioisotopes; Humans; Iodine Radioisotopes; Leukopenia; Male; Methods; Phosphorus Radioisotopes; Prostatic Neoplasms; Radiotherapy Dosage; Rectal Diseases; Time Factors; Ulcer; Urethral Stricture; Urinary Calculi | 1976 |
Treatment of metastatic carcinoma of the prostate to bone with parathormone and radioactive phosphorous.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Bone Neoplasms; Calcium; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Parathyroid Hormone; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms | 1974 |
Radiophosphorous (P32) treatment in carcinoma of the breast and prostate: report of 39 cases.
Topics: Blood Platelets; Bone Neoplasms; Breast Neoplasms; Calcium; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Pain, Intractable; Palliative Care; Parathyroid Hormone; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1974 |
[Combination of P32 and testosterone in the treatment of pain due to osseous metastasis of prostate neoplasms].
Topics: Bone Neoplasms; Drug Combinations; Drug Evaluation; Humans; Injections, Intravenous; Male; Neoplasm Metastasis; Pain; Palliative Care; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1974 |
Paraplegia and paraparesis due to prostatic cancer. Use of intravenous diethylstilbestrol diphosphate.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Castration; Diethylstilbestrol; Estrogens; Humans; Infusions, Parenteral; Iowa; Laminectomy; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Paralysis; Paraplegia; Phosphorus Radioisotopes; Prostatic Neoplasms | 1974 |
Proceedings: Testosterone potentiated radiophosphorus therapy of osseous metastases in prostatic cancer.
Topics: Administration, Oral; Aged; Bone Neoplasms; Female; Hematopoiesis; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Phosphorus Radioisotopes; Prostatic Neoplasms; Spinal Cord Compression; Spinal Neoplasms; Testosterone; Thrombocytopenia | 1974 |
[Indications of radioactivity of prostatic secretion by means of P32 in prostatic diseases].
Topics: Adolescent; Adult; Age Factors; Aged; Body Fluids; Diagnosis, Differential; Humans; Male; Middle Aged; Phosphorus Radioisotopes; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Radioactivity | 1973 |
Parathormone-potentiated radiophosphorus therapy in prostatic carcinoma.
Topics: Bone Neoplasms; Humans; Male; Neoplasm Metastasis; Parathyroid Hormone; Phosphorus Radioisotopes; Prostatic Neoplasms; Radiotherapy Dosage | 1973 |
Editorial: Treatment of bone metastases from carcinoma of prostate with parathyroid hormone and radioactive phosphorus.
Topics: Bone Neoplasms; Humans; Male; Neoplasm Metastasis; Parathyroid Hormone; Phosphorus Radioisotopes; Prostatic Neoplasms | 1973 |
The evaluation of methods applied in diagnosis of prostatic cancer.
Topics: 17-Ketosteroids; Biopsy; Estrogens; Humans; Male; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms; Radiography; Seminal Vesicles | 1962 |
The early diagnosis of prostatic malignancy by the use of P32.
Topics: Early Diagnosis; Humans; Male; Phosphorus; Phosphorus Radioisotopes; Phosphorus, Dietary; Prostatic Neoplasms; Radioactivity | 1961 |
Experiences with P-32 in treatment of metastatic carcinoma of prostate: a preliminary report.
Topics: Carcinoma; Humans; Male; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms | 1961 |
[Attempted diagnosis of prostatic cancer with the aid of P32].
Topics: Humans; Male; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms | 1961 |
Metastatic carcinoma of the prostate: response to radioactive phosphorus (P32). A case report.
Topics: Carcinoma; Humans; Male; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms | 1959 |
Use of radioactive P-32 in treating skeletal metastases from carcinoma of the prostate.
Topics: Bone and Bones; Bone Neoplasms; Carcinoma; Humans; Male; Neoplasms; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms | 1959 |
The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate.
Topics: Bone and Bones; Bone Neoplasms; Breast; Breast Neoplasms; Humans; Male; Neoplasms; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms; Testosterone | 1958 |
Destruction of the hypophysis with radioactive colloidal chromic phosphate in cancer of the prostate.
Topics: Chromium Compounds; Humans; Male; Neoplasms; Phosphates; Phosphorus; Phosphorus Radioisotopes; Pituitary Gland; Prostatic Neoplasms | 1958 |
Further experiences in treatment of carcinoma of prostate with radioactive chromic phosphate and yttrium chloride.
Topics: Carcinoma; Chromium Compounds; Gold Radioisotopes; Humans; Male; Phosphates; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms; Yttrium | 1957 |
[Several uses of radioactive isotopes in urology].
Topics: Gold Radioisotopes; Humans; Male; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms; Radioisotopes; Urinary Bladder Neoplasms; Urology | 1955 |
Treatment of prostatic carcinoma with radioactive colloidal chromic phosphate (p32); a preliminary report.
Topics: Chromium Compounds; Humans; Male; Phosphates; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms | 1954 |
Intraprostatic injections of radioactive colloids. II. Distribution within the prostate and tissue changes following injection in the dog.
Topics: Animals; Colloids; Dogs; Gold Radioisotopes; Humans; Injections; Male; Phosphorus; Phosphorus Radioisotopes; Prostatic Neoplasms | 1954 |
The treatment of prostatic carcinoma with radioactive colloidal chromic phosphate (P32); preliminary report.
Topics: Chromium Compounds; Humans; Male; Phosphates; Phosphorus; Phosphorus Radioisotopes; Phosphorus, Dietary; Prostatic Neoplasms | 1953 |